Currently, data on pathogenic variants in the CHEK2 gene and their impact on cancer risk are lacking. This study aimed to explore the characteristics of breast cancer (BC) patients from families with CHEK2 pathogenic variants in Slovenia.
In the years 2014 to 2019, CHEK2 pathogenic variants/likely pathogenic variants (PV/LPVs) were found in probands from 50 different families who underwent genetic counseling and testing using a multigene panel at the authors’ institution. Altogether, the study enrolled 75 individuals from 50 CHEK2 families who were carriers of a CHEK2 PV/LPV. The clinical data on 41 BC patients with CHEK2 PV/LPV and other carriers of CHEK2 PV/LPV from Slovenia were collected and analyzed.
Breast cancer was diagnosed in 41 of 75 CHEK2 PV/LPV carriers (40 females, 1 male). The mean age at BC diagnosis was 42.8 years (range, 21–63 years), and 27 (65.8%) of the 41 of patients with BC had a positive family history for BC. Contralateral BC (CBC) was observed in 8 (19.5%) of the 41 patients (mean age, 55.6 years). Of 12 patients with human epidermal growth factor receptor 2 (HER2)-positive tumor type, a c.444+1G > A PV/LPV was detected in 4 patients, c.349A > G in 3 patients, deletion of exons 9–10 in 3 patients, deletion of exon 8 in 1 patient, and c.1427C > T PV/LPV in 1 patient.
Bilateral BC was diagnosed in as many as 19.5% of the Slovenian BC patients with CHEK2 PV/LPVs. Breast cancer associated with a germline CHEK2 PV/LPV occurs in younger patients compared with sporadic BC.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Kapoor NS, Curcio LD, Blakemore CA, et al. Multigene panel testing detects equal rates of pathogenic BRCA1/2 mutations and has a higher diagnostic yield compared to limited BRCA1/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol. 2015;22:3282–8.
Cybulski C, Górski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75:1131–5.
Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295:1379–88.
Kleiblova P, Stolarova L, Krizova K, et al. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Int J Cancer. 2019;145:1782–97.
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic NCCN Clinical Practice Guidelines in Oncology, version 1.2020, 4 December 2019. Retrieve 9 April 2020 at https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf, 2020.
Genetic/Familial High-Risk Assessment: Colorectal, NCCN Clinical Practice Guidelines In Oncology, version 3.2019, 13 December 2019. Retrieved 9 April 2020 at https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf, 2020.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.
Plon SE, Eccles DM, Easton D, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–91.
Stegel V, Krajc M, Zgajnar J, et al. The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. BMC Med Genet. 2011;12:9.
Krajc M, Zadnik V, Novaković S, et al. Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening. Clin Genet. 2014;85:59–63.
Novaković S, Milatović M, Cerkovnik P, et al. Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families. Int J Oncol. 2012,41:1619–27.
Gornjec A, Novakovic S, Stegel V, et al. Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma. BMC Cancer. 2019;19:296.
Cvelbar M, Hocevar M, Novakovic S, et al. Genetic counselling, BRCA1/2 status and clinic-pathologic characteristics of patients with ovarian cancer before 50 years of age. Radiol Oncol. 2017;51:187–94.
Besic N, Cernivc B, de Grève J, et al. BRCA2 gene mutations in Slovenian male breast cancer patients. Genet Test. 2008;12:203–9.
Liang M, Zhang Y, Sun C, et al. Association between CHEK2*1100delC and breast cancer: a systematic review and meta-analysis. Mol Diagn Ther. 2018;22:397–407.
Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31:55–9.
CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delCand susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9065 controls from 10 studies. Am J Hum Genet. 2004;74:1175–82.
Vahteristo P, Bartkova J, Eerola H, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002;71:432–8.
Iniesta MD, Gorin MA, Chien LC, et al. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America. Cancer Genet Cytogenet. 2010;202:136–40.
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–16.
Kuusisto, Bebel A, Vihinen M, et al. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res. 2011;13:R20.
Rasmussen CB, Kjaer SK, Ejlertsen B, et al. Incidence of metachronous contralateral breast cancer in Denmark 1978–2009. Int J Epidemiol. 2014;43:1855–64.
Gogas J, Markopoulos C, Skandalakis P, Gogas H. Bilateral breast cancer. Am Surg. 1993;59:733–5.
Skasko E, Kluska A, Niwińska A, et al. Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations, and positive family history of cancer. Onkologie. 2009;32:182–8.
Domagala P, Wokolorczyk D, Cybulski C, et al. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;132:937–45.
Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6:R149–56.
Besic N, Kramaric A, Podnar B, et al. Factors correlated to successful surgical treatment of 181 non-palpable invasive breast carcinomas. Breast. 2009;18:294–8.
Liu C, Wang Y, Wang QS, Wang YJ. The CHEK2 I157T variant and breast cancer susceptibility: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:1355–60.
Näslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen general population study. J Clin Oncol. 2016;34:1208–16.
Akdeniz D, Schmidt MK, Seynaeve CM, et al. Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis. Breast. 2019;44:1–14.
Teoh V, Tasoulis MK, Gui G. Contralateral prophylactic mastectomy in women with unilateral breast cancer who are genetic carriers, have a strong family history, or are just young at presentation. Cancers Basel. 2020;12:E140.
This research was funded by the Ministry of Education, Science and Sport of the Republic of Slovenia, grant nos. P3-0289 and P3-0352.
There are no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Nizic-Kos, T., Krajc, M., Blatnik, A. et al. Bilateral Disease Common Among Slovenian CHEK2-Positive Breast Cancer Patients. Ann Surg Oncol (2020). https://doi.org/10.1245/s10434-020-09178-y